Sciomics are proud to announce the publication of their study on disease severity markers in Covid-19 in Communications Medicine.
They have identified and verified protein biomarkers panels which can be measured in the first days of a Covid-19 disease predicting a severe outcome.
Using these biomarkers, patients at high risk of developing a severe or critical disease may be selected for treatment with specialized therapeutic options such as neutralizing antibodies or antivirals. Early therapy through early stratification may not only have a positive impact on the outcome of individual COVID-19 patients but could additionally prevent hospitals from being overwhelmed in potential future pandemic situations.
Their efforts on this important topic addressing pandemic preparedness continue in a collaborative project selected by Eurostars for funding.
Please get in touch with Sciomics for more information or if you are interested to collaborate.
A huge thank you to their collaboration partners Anahita Fathi, MD, Christine Dahlke, Marylyn Martina Addo at Universitätsklinikum Hamburg Eppendorf and Uta Merle at University Hospital Heidelberg as well as to the whole team at Sciomics - Enabling Precision Medicine !
Link to the article: https://rdcu.be/c9GUS
Hufnagel, K., Fathi, A. et al. Discovery and systematic assessment of early biomarkers that predict progression to severe COVID-19 disease. Commun Med 3, 51 (2023). https://lnkd.in/eeeF6dhY